Cost Analyst at Emzor Pharmaceutical Industries Limited

Emzor Pharmaceutical Industries Limited is a wholly private indigenous pharmaceutical manufacturing group founded in 1984 by Dr. Stella C. Okoli, OON. The company is into the manufacture of high quality pharmaceutical products and medical consumables. Today, Emzor has become a household name in Nigeria and a leader in the pharmaceutical market that is known for quality products at prices that offer real value. These products are widely distributed throughout Nigeria and the West African coast. Our commitment is to produce and deliver flawless products on time and every time.

We are recruiting to fill the positions below:

Job Title: Cost Analyst

Location: Lagos
Job Schedule: Full-time

Job Description / Responsibilities

• To determine the landing cost of imported raw and packaging materials
• To ascertain unit cost of finished goods for Emzor pharmaceutical industries products.
• To promptly evaluate sales or marketing proposal for discount, promotions and other sales push and advice management.
• To prepare factory efficiency reports such as downtime, output and yield analysis, labor efficiencies and wastage reports.
• Continuous check for correctness of boom material mix and cost on oracle ERP system.
• To evaluate and appraise project tenders and special projects for management approval.
• To evaluate and appraise public private partnership projects for management considerations.

Qualification

• HND or BSC or evidence of certification in view. plus, part qualification of any of the accounting professional body – ICAN OR ACCA
• Knowledge and practical use of excel
• Confidence, initiative and must be a team player
• Great attention to details.
• 2-3 years on the job experience on listed areas

How to Apply
Interested and qualified candidates should send their CV and Cover Letter to: [email protected] using "Application for Cost Analyst" as the subject of the mail.

Note: Only shortlisted candidates will be contacted

Application Deadline  21st June, 2025.